UNITED STATES SECURITIES AND EXCHANGE COMMISSION January 8, 2015

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Sucampo Pharmaceuticals, Inc.

File No. 1-33609 - CF#31782

Sucampo Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on November 7, 2014.

Based on representations by Sucampo Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.1	through January 1, 2024
Exhibit 10.2	through September 30, 2024
Exhibit 10.3	through September 30, 2024
Exhibit 10.4	through December 31, 2020
Exhibit 10.6	through December 31, 2020

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary